Full-Life Technologies has appointed Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD as Chief Scientific Officer. Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years. His work was instrumental to the development of Erbitux®, a monoclonal therapeutic antibody targeting EGFR, as well as the successful clinical development of other anti-cancer therapeutic antibodies, including targeted drug conjugates. Dr. Liu is a leading peptide chemist who served as Head of Chemistry at Novo Nordisk, and in 2020, as Co-founder and CEO of Focus-X, a peptide-focused radiopharmaceutical company recently acquired by Full-Life. 
 
“Dr. Heeger brings to Full-Life great breadth of expertise and an outstanding track record in designing and executing clinical strategies for targeted oncology therapeutics, in both early and late-stage development,” said Lanny Sun, Full-Life’s Co-founder, Chairman and CEO. “He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials. Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk. He led Focus-X to build a promising radiopharmaceutical pipeline within two years of inception. He will further strengthen our discovery capabilities, including our radionuclide-drug conjugate (RDC) platforms and therapeutic programs. We are excited to welcome these senior leaders to our team.”
 
Dr. Liu, prior to founding Focus-X, served as the Head of Chemistry at Novo Nordisk Research Centers in the US, leading peptide and protein therapeutics discovery. Previously, Dr. Liu was the Head of Chemistry at Calibrium LLC, where he played instrumental roles in building the company’s pipeline until its acquisition by Novo Nordisk. Dr. Liu began his industrial career at Eli Lilly, where he led multiple peptide lead optimization efforts and established the well-recognized modern insulin chemistries. Prior to Lilly, Dr. Liu worked at National Cancer Institute focusing on cancer drug discovery. Dr. Liu has discovered five compounds that progressed into human studies, including NNC0480-0389 (Phase II). He also contributed to the discovery of LY3209590 (Phase III) and the FDA approved drug Lyumjev® (insulin lispro-aabc).